Clavulanic acid protects neurons in pharmacological models of neurodegenerative diseases

Drug Development Research

Volumn 71, Issue 6, 2010, Pages 351-357

  Huh, Youngbuhm ^a   Ju, Mi Sun ^b   Park, Hanbyeol ^b   Han, Shengjun ^a   Bang, Yu Mi ^a   Ferris, Craig F ^c   Koppell, Gary A ^d   King, Jean A ^e   Kim, Minkyu Leo ^f   Kim, Deog Joong ^f   Ahn, Chang Ho ^f   Oh, Myung Sook ^b  

^a Kyung Hee University Hospital   (South Korea)

^b Kyung Hee University   (South Korea)

^c NORTHEASTERN UNIVERSITY   (United States)

^d Rexahn Pharmaceuticals Inc ^*  (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f Rexahn Pharmaceuticals Inc   (United States)

Author keywords

Clavulanic acid; Kainic acid; MPTP; Neuroprotection

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CLAVULANIC ACID; KAINIC ACID;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEATH; BRAIN NERVE CELL; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG MECHANISM; HIPPOCAMPUS; HISTOCHEMISTRY; MALE; MOTOR PERFORMANCE; MOUSE; NEUROMODULATION; NEUROPHARMACOLOGY; NEUROPROTECTION; NONHUMAN; RAT; RODENT; TISSUE SECTION;

EID: 77957196022     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20378     Document Type: Article

References (30)

1. Baran H. 2006. Alterations of taurine in the brain of chronic kainic acid epilepsy model. Amino Acids 31:303-307. (Pubitemid 44537056)
2. Brookmeyer R, Gray S, Kawas C. 1998. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88:1337-1342. (Pubitemid 28402270)
3. Chan JS, Kim DJ, Ahn CH, Oosting RS, Olivier B. 2009. Clavulanic acid stimulates sexual behaviour in male rats. Eur J Pharmacol 609:69-73.
4. Dauer W, Przedborski S. 2003. Parkinson's disease: mechanisms and models. Neuron 39:889-909.
5. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alperovitch A, Rocca WA. 1997. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 62:10-15.
6. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. 2007. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68:384-386.
7. Findley LJ. 2007. The economic impact of Parkinson's disease. Parkinsonism Relat Disord 13 Suppl:S8-S12.
8. Fujikawa T, Miguchi S, Kanada N, Nakai N, Ogata M, Suzuki I, Nakashima K. 2005. Acanthopanax senticosus Harms as a prophylactic for MPTP-induced Parkinson's disease in rats. J Ethnopharmacol 97:375-381. (Pubitemid 40222042)
9. Katagiri N, Chida S, Abe K, Nojima H, Kitabatake M, Hoshi K, Horiguchi Y, Taguchi K. 2010. Preventative effects of 1,3-dimethyl- and 1,3-dimethyl-N- propargyl-1,2,3,4-tetrahydroisoquinoline on MPTP-induced Parkinson's disease-like symptoms in mice. Brain Res 1321:133-142.
10. Kim DJ, King JA, Zuccarelli L, Ferris CF, Koppel GA, Snowdon CT, Ahn CH. 2009. Clavulanic acid: a competitive inhibitor of beta-lactamases with novel anxiolytic-like activity and minimal side effects. Pharmacol Biochem Behav 93:112-120.
11. Lohle M, Reichmann H. 2010. Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough. J Neurol Sci 289:104-114.
12. Nakagawa H, Yamada M, Tokiyoshi K, Miyawaki Y, Kanayama T. 1994. Penetration of potassium clavulanate/ticarcillin sodium into cerebrospinal fluid in neurosurgical patients. Jpn J Antibiot 47:93-101. (Pubitemid 24057778)
13. Ogawa N, Mizukawa K, Hirose Y, Kajita S, Ohara S, Watanabe Y. 1987. MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behavior. Eur Neurol 26:16-23. (Pubitemid 17047054)
14. Olanow CW. 2009. Can we achieve neuroprotection with currently available anti-parkinsonian interventions? Neurology 72:S59-S64.
15. Olanow CW, Stern MB, Sethi K. 2009. The scientific and clinical basis for the treatment of Parkinson disease. 2009). Neurology 72:S1-S136.
16. Paxinos G, Franklin K. 2003. The mouse brain in stereotaxic coordinates: Compact Second Edition, 2nd ed. New York: Academic Press.
17. Paxinos G, Watson C. 2004. The rat brain in stereotaxic coordinates: the new coronal set. New York: Academic Press.
18. Payne DJ, Cramp R, Winstanley DJ, Knowles DJ. 1994. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases. Antimicrob Agents Chemother 38:767-772. (Pubitemid 24114016)
19. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes HM, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB. 2005. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433:73-77.
20. Sadgrove MP, Chad JE, Gray WP. 2005. Kainic acid induces rapid cell death followed by transiently reduced cell proliferation in the immature granule cell layer of rat organotypic hippocampal slice cultures. Brain Res 1035:111-119.
21. Salloway S, Mintzer J, Weiner MF, Cummings JL. 2008. Diseasemodifying therapies in Alzheimer's disease. Alzheimers Dement 4:65-79.
22. Samii A, Nutt JG, Ransom BR. 2004. Parkinson's disease. Lancet 363:1783-1793.
23. Selkoe DJ. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81:741-766.
24. Sloane PD, Zimmerman S, Suchindran C, Reed P, Wang L, Boustani M, Sudha S. 2002. The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health 23:213-231. (Pubitemid 34508073)
25. Smeyne RJ, Jackson-Lewis V. 2005. The MPTP model of Parkinson's disease. Brain Res Mol Brain Res 134:57-66.
26. Surmeier DJ. 2007. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol 6:933-938. (Pubitemid 47405004)
27. Takahata K, Shimazu S, Yoneda F, Ogawa M, Iida Y, Saji H. 2003. Effects of monoamine oxidase inhibitors on the diethyldithiocarbamate-induced enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in C57BL/6 mice. J Neural Transm 110:859-869.
28. Voss T, Ravina B. 2008. Neuroprotection in Parkinson's disease: myth or reality? Curr Neurol Neurosci Rep 8:304-309.
29. Yacoubian TA, Standaert DG. 2009. Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta 1792:676-687.
30. Zanier ER, Lee SM, Vespa PM, Giza CC, Hovda DA. 2003. Increased hippocampal CA3 vulnerability to low-level kainic acid following lateral fluid percussion injury. J Neurotrauma 20:409-420.